T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity
- 8 June 2013
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 139 (3) , 657-665
Abstract
Numerous lines of evidence demonstrate that breast cancer is immunogenic; yet, there are few biologically relevant immune targets under investigation restricting the exploration of vaccines to limited breast cancer subtypes. Insulin-like growth factor-I receptor (IGF-IR) is a promising vaccine candidate since it is overexpressed in most breast cancer subtypes, is part of a dominant cancer growth pathway, and has been validated as a therapeutic target. We questioned whether IGF-IR was immunogenic in cancer patients. IGF-IR-specific IgG antibodies were significantly elevated in early-stage breast cancer patients at the time of diagnosis as compared to volunteer donors (p = 0.04). Predicted T-helper epitopes, derived from the IGF-IR extracellular and transmembrane domains, elicited a significantly higher incidence of Th2 immunity in breast cancer patients as compared to controls (p = 0.01). Moreover, the magnitude of Th2 immunity was greater in breast cancer patients compared to controls (p = 0.02). In contrast, both breast cancer patients and volunteer donors demonstrated a similar incidence of Th1 immunity to IGF-IR domains with the predominant response directed against epitopes in the intracellular domain of the protein. As the incidence of IGF-IR type I immunity was not associated with a breast cancer diagnosis, we questioned whether other factors were contributing to the presence of IGF-IR-specific T-cells in both populations. While age was not associated with Th1 immunity, we observed a significantly greater magnitude of IGF-IR IFN-γ-secreting T-cells in obese subjects as compared to overweight (p < 0.001) or healthy-weight (p = 0.006) subjects, regardless of breast cancer diagnosis. No significant difference was observed for Th2 incidence or magnitude when stratified by age (p = 0.174, p = 0.966, respectively) or body mass index (p = 0.137, p = 0.174, respectively). Our data demonstrate that IGF-IR is a tumor antigen and IGF-IR-specific Th1 immunity may be associated with obesity rather than malignancy.Keywords
This publication has 37 references indexed in Scilit:
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13Cancer Immunology, Immunotherapy, 2011
- High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR TherapyClinical Cancer Research, 2011
- Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammationJournal of Experimental Medicine, 2011
- The dendritic cell–tumor cross-talk in cancerCurrent Opinion in Immunology, 2011
- T‐Cell Recruitment and Th1 Polarization in Adipose Tissue During Diet‐Induced Obesity in C57BL/6 MiceObesity, 2010
- Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast CancerCancer Research, 2008
- Appearance of B220low autoantibody-producing B-1 cells at neonatal and older stages in miceClinical and Experimental Immunology, 2008
- Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell–associated antigensJournal of Clinical Investigation, 2007
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor developmentJournal of Experimental Medicine, 2007